Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?

By Yahoo! Finance | Sep 16, 2024 at 05:21 AM EST

Abbott Laboratories has experienced fluctuating revenue due to the pandemic, but its diabetes care segment, especially the FreeStyle Libre CGM devices, has shown consistent growth. With new products like Libre Rio and Lingo, Abbott aims to reach $10 billion in annual sales by 2028.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.